In the Kaplan–Meier curve, the presence of galectin-3 ≥6.49 ng/mL in T2DM patients was significantly associated with a decrease in the number of patients who remained event-free, compared to those with galectin-3 below that value (Log rank test 10.5, p = 0.001) (Figure 1). This evidence concerns the gene LGALS3 and type 2 diabetes mellitus.